Literature DB >> 10694738

Multi-state models for bleeding episodes and mortality in liver cirrhosis.

P K Andersen1, S Esbjerg, T I Sorensen.   

Abstract

Data from a controlled clinical trial in liver cirrhosis are used to illustrate that multi-state models may be a useful tool in the analysis of data where survival is the ultimate outcome of interest but where intermediate, transient states are identified. We compare models for the marginal survival time distribution with models including transient states, both with respect to their clinical interpretation and with respect to the precision of survival probability estimates obtained from the various models. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694738     DOI: 10.1002/(sici)1097-0258(20000229)19:4<587::aid-sim358>3.0.co;2-0

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  19 in total

1.  Analysis of the bypass angioplasty revascularization investigation trial using a multistate model of clinical outcomes.

Authors:  Xiao Zhang; Quanlin Li; Andre Rogatko; Mourad Tighiouart; Regina M Hardison; Maria Mori Brooks; Sheryl F Kelsey; Sanjay Kaul; C Noel Bairey Merz
Journal:  Am J Cardiol       Date:  2015-02-02       Impact factor: 2.778

2.  Asymptotic theory for the Cox semi-Markov illness-death model.

Authors:  Youyi Shu; John P Klein; Mei-Jie Zhang
Journal:  Lifetime Data Anal       Date:  2007-03       Impact factor: 1.588

3.  Nonparametric estimation of transition probabilities in a non-Markov illness-death model.

Authors:  Luís Meira-Machado; Jacobo de Uña-Alvarez; Carmen Cadarso-Suárez
Journal:  Lifetime Data Anal       Date:  2006-08-18       Impact factor: 1.588

4.  Methodological considerations for disentangling a risk factor's influence on disease incidence versus postdiagnosis survival: The example of obesity and breast and colorectal cancer mortality in the Women's Health Initiative.

Authors:  Elizabeth M Cespedes Feliciano; Ross L Prentice; Aaron K Aragaki; Marian L Neuhouser; Hailey R Banack; Candyce H Kroenke; Gloria Y F Ho; Oleg Zaslavsky; Howard D Strickler; Ting-Yuan David Cheng; Rowan T Chlebowski; Nazmus Saquib; Rami Nassir; Garnet Anderson; Bette J Caan
Journal:  Int J Cancer       Date:  2017-08-31       Impact factor: 7.396

5.  A comparison of time-homogeneous Markov chain and Markov process multi-state models.

Authors:  Lijie Wan; Wenjie Lou; Erin Abner; Richard J Kryscio
Journal:  Commun Stat Case Stud Data Anal Appl       Date:  2017-08-18

6.  Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative.

Authors:  Kerryn W Reding; Aaron K Aragaki; Richard K Cheng; Ana Barac; Sylvia Wassertheil-Smoller; Jessica Chubak; Marian C Limacher; W Gregory Hundley; Ralph D'Agostino; Mara Z Vitolins; Theodore M Brasky; Laurel A Habel; Eric J Chow; Rebecca D Jackson; Chu Chen; April Morgenroth; Wendy E Barrington; Matthew Banegas; Matthew Barnhart; Rowan T Chlebowski
Journal:  Oncologist       Date:  2020-04-06

7.  Joint modeling approach for semicompeting risks data with missing nonterminal event status.

Authors:  Chen Hu; Alex Tsodikov
Journal:  Lifetime Data Anal       Date:  2014-01-16       Impact factor: 1.588

8.  Multi-state models for the analysis of time-to-event data.

Authors:  Luís Meira-Machado; Jacobo de Uña-Alvarez; Carmen Cadarso-Suárez; Per K Andersen
Journal:  Stat Methods Med Res       Date:  2008-06-18       Impact factor: 3.021

9.  Estimation with Right-Censored Observations Under A Semi-Markov Model.

Authors:  Lihui Zhao; X Joan Hu
Journal:  Can J Stat       Date:  2013-06       Impact factor: 0.875

10.  An ensemble survival model for estimating relative residual longevity following stroke: Application to mortality data in the chronic dialysis population.

Authors:  Milind A Phadnis; James B Wetmore; Theresa I Shireman; Edward F Ellerbeck; Jonathan D Mahnken
Journal:  Stat Methods Med Res       Date:  2015-09-24       Impact factor: 3.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.